Advertisement

Cancer Causes & Control

, Volume 7, Issue 3, pp 305–311 | Cite as

A program for eradication of hepatitis B from Taiwan by a 10-year, four-dose vaccination program

  • Ding-Shinn Chen
  • Hsu-Mei Hsu
  • Charles L. Bennett
  • Tammy S. Pajeau
  • Baruch Blumberg
  • Po-ya Chang
  • Kusuya Nishioka
  • Andrew Huang
  • Juei-Low Sung
Research Papers

Approximately 15 percent of the Taiwanese population are chronic carriers of hepatitis B virus (HBV), among the highest rates in Asia. In July 1984, the Taiwanese government initiated a nationwide HBV-vaccination program. The program began with educational efforts and voluntary prenatal screening for HBsAg. Infants of HBsAg-carrier mothers received a four-dose regimen of hepatitis B vaccine. Those born to highly infectious mothers also received a dose of hepatitis-B immune globulin within 24 hours after birth. Seroepidemiologic studies were conducted using a random sample of infants. Serum samples were collected at 18, 24, 36, and 48 months and analyzed via radioimmunoassay for HBsAg, anti-HBs, and anti-HBc. Infants of highly infectious mothers had HBsAg positivity rates of 14.2 percent (vaccine plus HBIG) and 19.7 percent (vaccine only) when on schedule, and 17.0 percent when off schedule. Infants of moderately infectious mothers had an HBsAg positivity rate of 3.0 percent when on schedule and 6.4 percent when off schedule. These low positivity rates persisted throughout the 48-month follow-up period. This represents a dramatic improvement upon the 40 to 96 percent vertical transmission rate seen before the program implementation. This program demonstrates that mass immunoprophylaxis for HBV is feasible, and provides practical strategies for other Asian countries.

Key words

Immunoprophylaxis hepatitis B virus perinatal infection Taiwan 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Department of Health. The population. In: Hsu TC, ed. Health and Medicine in Taiwan Area, Republic of China. Taipei, Taiwan: Department of Health, Executive Yuan, 1985: 3–4.Google Scholar
  2. 2.
    Blumberg BS, Alter HJ, Vinisch S. A new antigen in leukemic sera. JAMA 1965; 191: 541–6.Google Scholar
  3. 3.
    Chen DS. From hepatitis to hepatoma: Lessons from type B viral hepatitis. Science 1993; 262: 369–70.Google Scholar
  4. 4.
    Hsu HM, Chenn DS, Chuan CH, et al. Efficacy of a mass hepatitis B vaccination program in Taiwan. JAMA 1989; 260: 2231–5.Google Scholar
  5. 5.
    Chen DS, Sung JL. Hepatitis B virus infection and chronic liver diseases in Taiwan. Acta Hepatol-Gastroenterol 1987; 25: 423–30.Google Scholar
  6. 6.
    Sung JL, Chen DS, Lai My, et al. Epidemiological study on hepatitis B virus infection in Taiwan. Chin J Gastroenterol 1984; 1: 1–9.Google Scholar
  7. 7.
    Beasley RP, Hwang LY, Lin CC, et al. Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22,707 men in Taiwan. Lancet 1981; 2: 1129–33.Google Scholar
  8. 8.
    Stevens CE, Beasley RP, Tsui J, et al. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975; 292: 771–4.Google Scholar
  9. 9.
    Chen DS, Hsu NHM, Sung JL, et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface-antigen carrier mothers. JAMA 1987; 257: 2597–603.Google Scholar
  10. 10.
    Hepatitis Control. Taipei, Taiwan: Monograph of the Science and Technology Advisory Group of the Executive Yuan of Taiwan, 1988: 1–39.Google Scholar
  11. 11.
    Tada H, Yanagida M, Misina J, et al. Combined passive and active immunization for preventing perinatal transmission of hepatitis B virus carrier state. Pediatrics 1982; 90: 613–9.Google Scholar
  12. 12.
    Chunsittiwat S. Cost-effectiveness of hepatitis B control programme in Thailand. In: Sittaprecha V, ed. Viral Hepatitis. Bangkok, Thailand: Medical Press, 1986: 101.Google Scholar
  13. 13.
    Sung JL. Control of hepatitis B in Taiwan. In: Sung JL, Chen DS, eds. Viral Hepatitis and Hepatocellular Carcinoma. Hong Kong: Excerpta Medica, Current Clinical Practice Series 57, 1990: 435.Google Scholar
  14. 14.
    Sung JL, Chen DS, Lee CY, Hsu HM, Low KJ. Prevention of hepatocellular carcinoma. In: Ronald Ellis, ed. Hepatitis B Vaccines in Clinical Practice. New York, NY (USA): Marcel Dekker, 1993: 263–78.Google Scholar
  15. 15.
    Sung JL. Control of Hepatitis B in Taiwan. In: Proceedings of the Second International Conference on Viral Hepatitis and Hepatocellular Carcinoma. Taipei, Taiwan, December 1988.Google Scholar
  16. 16.
    Ueda H. National immunization program against vertical transmission of hepatitis B virus. Kan-Tan-Sui (Japan) 1986; 12: 237–42.Google Scholar
  17. 17.
    Proceedings of the First International Conference on Cancer Prevention in Asia. Taipei, Taiwan, October 1994.Google Scholar

Copyright information

© Rapid Science Publishers 1996

Authors and Affiliations

  • Ding-Shinn Chen
    • 6
  • Hsu-Mei Hsu
    • 5
  • Charles L. Bennett
    • 1
  • Tammy S. Pajeau
    • 1
  • Baruch Blumberg
  • Po-ya Chang
    • 5
  • Kusuya Nishioka
    • 7
  • Andrew Huang
    • 2
    • 4
  • Juei-Low Sung
    • 3
  1. 1.Lakeside VA Medical Center and Northwestern UniversityChicagoUSA
  2. 2.Sun Yat-Sen Cancer CenterChina
  3. 3.Department of Health of the Republic of ChinaHepatitis Control CommitteeChina
  4. 4.Duke UniversityDurhamUSA
  5. 5.Department of Health of the Republic of ChinaChina
  6. 6.National Taiwan University College of Medicine and the Science and Technology Advisory Group, Executive YuanTaipeiTaiwan, Republic of China
  7. 7.Viral Hepatitis Research Foundation of JapanJapan

Personalised recommendations